6-fluoro-2,3-dihydrospiro[indene-1,3'-pyrrolidine]-2',5'-dione | 956142-24-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6-fluoro-2,3-dihydrospiro[indene-1,3'-pyrrolidine]-2',5'-dione
• 英文别名: 5-Fluorospiro[1,2-dihydroindene-3,3'-pyrrolidine]-2',5'-dione
• CAS: 956142-24-8
• 化学式: C₁₂H₁₀FNO₂
• 分子量: 219.215
• InChiKey: XIDJCWMBSQTYCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-fluoro-2,3-dihydrospiro[indene-1,3'-pyrrolidine]-2',5'-dione 在 硼烷四氢呋喃络合物 、 盐酸 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以87.6%的产率得到6-fluoro-2,3-dihydrospiro[indene-1,3'-pyrrolidine]
  参考文献：
  名称：

  WO2007/125061

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氟-1-茚酮 在 硫酸 、 ammonium acetate 、 水 、 溶剂黄146 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 16.0h， 生成 6-fluoro-2,3-dihydrospiro[indene-1,3'-pyrrolidine]-2',5'-dione
  参考文献：
  名称：

  WO2007/125061

  摘要：

  公开号：

文献信息

• SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS
  申请人：Bertani Barbara

  公开号：US20100063078A1

  公开（公告）日：2010-03-11

  The present invention relates to novel compounds of formula (I) or salts thereof: wherein A is a substituent selected in the group consisting of P, P1, P2 and P3 wherein P is P1 is P2 is P3 is p is an integer ranging from 0 to 4; R 4 is selected in the group consisting of halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl, SF 5 and a 5- or 6-membered monocyclic heteroaryl group; and when p is an integer ranging from 2 to 4, each R 4 may be the same or different; R 2 is hydrogen or C 1-4 alkyl; q is 3, 4 or 5; n is 0, 1 or 2; X is —CR 1 R 3 — or —O—; R 1 is selected in the group consisting of hydrogen, C 1-4 alkyl and fluorine; R 3 is selected in the group consisting of hydrogen, C 1-4 alkyl and fluorine; R 5 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 5 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 6 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 6 is a phenyl group, a 5-14 membered heterocyclic group and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 7 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 7 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 8 is selected in the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, C 3-7 cycloalkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and NR′R″; or R 8 is a phenyl group, a 5-14 membered heterocyclic group; and any of such phenyl or heterocyclic group is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; R 9 is selected in the group consisting of hydrogen, a phenyl group, a heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, and a 8- to 11-membered heteroaryl bicyclic, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; R 10 is C 1-4 alkyl; R 11 is hydrogen or C 1-4 alkyl; R′ is H, C 1-4 alkyl or C 1-4 alkanoyl; R″ is defined as R′; R′ and R″ taken together with the interconnecting nitrogen atom may form a 5-, 6-membered saturated or unsaturated heterocyclic ring; wherein R 5 , R 6 , R 7 and R 8 are not simultaneously other than hydrogen; wherein only one R 2 group ma be different from hydrogen and wherein when n is 0, X is a group —CR 1 R 3 —; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or to enhance cognition.

  本发明涉及公式（I）的新化合物或其盐：其中A是从P，P1，P2和P3组成的取代基的选择，其中P是，P1是，P2是，P3是，p是0到4的整数；R4被选择在卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基，SF5和5-或6-成员的单环杂芳基组成的群中；当p是2到4的整数时，每个R4可以相同或不同；R2是氢或C1-4烷基；q是3，4或5；n是0，1或2；X是—CR1R3—或—O—；R1被选择在氢，C1-4烷基和氟中；R3被选择在氢，C1-4烷基和氟中；R5被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R5是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R6被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R6是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R7被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R7是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R8被选择在氢，卤素，羟基，氰基，C1-4烷基，C3-7环烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和NR′R″的群中；或R8是苯基，5-14个成员的杂环基；任何这样的苯基或杂环基可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，卤代C1-4烷基，C1-4烷氧基，C1-4烷酰基和SF5的群中；R9被选择在氢，苯基，杂环基，5-或6-成员的单环杂芳基和8-到11-成员的杂芳双环中的一个，其中任何这样的基团可以选择地被1，2，3或4个取代基所取代，所述取代基被选择在卤素，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基和C1-4烷酰基的群中；R10是C1-4烷基；R11是氢或C1-4烷基；R′是H，C1-4烷基或C1-4烷酰基；R″被定义为R′；R′和R″与相互连接的氮原子一起可以形成5-，6-成员的饱和或不饱和杂环环；其中R5，R6，R7和R8不同时为除氢外的其他基团；其中只有一个R2基团可能与氢不同，当n为0时，X是一个—CR1R3—基团；用于其制备的过程，用于这些过程的中间体，包含它们的制药组合物以及它们作为多巴胺D3受体调节剂的用途，例如用于治疗药物依赖症，作为抗精神病药物，用于治疗强迫症谱系障碍，早泄或增强认知能力。
• PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES
  申请人：Amura Therapeutics Limited

  公开号：EP1546150B1

  公开（公告）日：2009-03-04
• US4307108A
  申请人：——

  公开号：US4307108A

  公开（公告）日：1981-12-22
• US4442114A
  申请人：——

  公开号：US4442114A

  公开（公告）日：1984-04-10
• US4471124A
  申请人：——

  公开号：US4471124A

  公开（公告）日：1984-09-11